Singapore markets closed

Nuvation Bio Inc. (NUVB)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
2.0500+0.0500 (+2.50%)
At close: 04:00PM EDT
2.0500 0.00 (0.00%)
After hours: 04:11PM EDT

Nuvation Bio Inc.

1500 Broadway
Suite 1401
New York, NY 10036
United States
332 208 6102

Full-time employees85

Key executives

NameTitlePayExercisedYear born
Dr. David T. Hung M.D.Founder, Pres, CEO & Director1.18MN/A1958
Ms. Jennifer A. FoxCFO & Sec.1.01MN/A1972
Dr. David C. Hanley Ph.D.Chief Technical Operations Officer497.14kN/A1970
Dr. Gary Hattersley Ph.D.Chief Scientific OfficerN/AN/A1967
Ms. Stacy MarkelChief People OfficerN/AN/A1965
Ms. Kerry A. WentworthChief Regulatory OfficerN/AN/A1973
Dr. David Liu M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

Corporate governance

Nuvation Bio Inc.’s ISS governance QualityScore as of 1 September 2022 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.